Nisa Investment Advisors LLC Acquires 7,333 Shares of CVS Health Corporation $CVS

Nisa Investment Advisors LLC increased its stake in shares of CVS Health Corporation (NYSE:CVS) by 2.2% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 338,831 shares of the pharmacy operator’s stock after buying an additional 7,333 shares during the period. Nisa Investment Advisors LLC’s holdings in CVS Health were worth $23,373,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in shares of CVS Health by 198.5% during the first quarter. GAMMA Investing LLC now owns 18,669 shares of the pharmacy operator’s stock worth $1,265,000 after purchasing an additional 12,415 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in CVS Health by 9.1% in the 1st quarter. Sequoia Financial Advisors LLC now owns 44,905 shares of the pharmacy operator’s stock worth $3,042,000 after purchasing an additional 3,748 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its stake in shares of CVS Health by 33.8% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 290,990 shares of the pharmacy operator’s stock valued at $19,715,000 after buying an additional 73,583 shares during the period. Creative Financial Designs Inc. ADV raised its position in shares of CVS Health by 39.5% during the first quarter. Creative Financial Designs Inc. ADV now owns 2,026 shares of the pharmacy operator’s stock worth $137,000 after acquiring an additional 574 shares during the last quarter. Finally, Western Wealth Management LLC bought a new stake in shares of CVS Health during the first quarter worth $226,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Buying and Selling

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director directly owned 22,156 shares in the company, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.22% of the company’s stock.

CVS Health Stock Up 1.1%

Shares of NYSE:CVS opened at $81.95 on Monday. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $83.52. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. The company has a market capitalization of $103.94 billion, a PE ratio of 22.89, a PEG ratio of 0.90 and a beta of 0.60. The company has a 50 day moving average price of $75.57 and a two-hundred day moving average price of $68.66.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The business had revenue of $98.92 billion during the quarter, compared to analysts’ expectations of $94.87 billion. During the same quarter in the prior year, the company earned $1.83 EPS. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Thursday, October 23rd will be given a $0.665 dividend. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. CVS Health’s payout ratio is currently 74.30%.

Analysts Set New Price Targets

Several brokerages have weighed in on CVS. Wells Fargo & Company boosted their price objective on CVS Health from $84.00 to $103.00 and gave the stock an “overweight” rating in a report on Tuesday, October 7th. Cowen reissued a “buy” rating on shares of CVS Health in a research note on Monday, August 4th. Morgan Stanley boosted their price target on shares of CVS Health from $82.00 to $89.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 14th. Zacks Research cut shares of CVS Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a research report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $83.38.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.